Rodney Burrow, MD
Family Medicine · Mount Pleasant, TXNPI 1871536714
Payments from drug & device makers
Across 176 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$377
- Lilly USA, LLC$366
- Novo Nordisk$284
- Corcept Therapeutics$206
- Bayer$163
- Johnson & Johnson$138
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,828100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $377 |
| Lilly USA, LLC | 22 | $366 |
| Novo Nordisk | 24 | $284 |
| Corcept Therapeutics | 6 | $206 |
| Bayer | 10 | $163 |
| Johnson & Johnson | 10 | $138 |
| Pfizer | 7 | $129 |
| Exact Sciences | 7 | $123 |
| Sanofi-aventis U.S. LLC | 8 | $118 |
| Merck | 8 | $110 |
| Abbott | 5 | $93 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| Amarin Pharma, Inc. | 5 | $76 |
| Dexcom, Inc. | 4 | $64 |
| Amgen | 4 | $63 |
| Phathom Pharmaceuticals, Inc. | 4 | $62 |
| Corium, LLC | 2 | $51 |
| Boehringer Ingelheim | 2 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| AstraZeneca | 3 | $42 |
| GSK | 1 | $40 |
| Eisai Inc. | 2 | $31 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
How this compares
$2,828 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $146,303 |
| JardianceEmpagliflozin | 143 | $135,721 |
| JanuviaSitagliptin Phosphate | 102 | $83,629 |
| FarxigaDapagliflozin Propanediol | 51 | $53,083 |
| MounjaroTirzepatide | 35 | $48,175 |
| VraylarCariprazine Hcl | 27 | $38,492 |
| TradjentaLinagliptin | 68 | $36,648 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $36,540 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $26,074 |
| TrulicityDulaglutide | 11 | $22,147 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $21,425 |
| VascepaIcosapent Ethyl | 35 | $18,509 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $17,618 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $16,626 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $47 | $172,369211 claims |
| Novo NordiskOzempic, Novolog | $284 | $148,829152 claims |
| MerckJanuvia | $110 | $83,629102 claims |
| Lilly USA, LLCMounjaro, Trulicity | $366 | $70,32246 claims |
| AstraZenecaFarxiga | $42 | $53,08351 claims |
| AbbVieVraylar, Combigan | $377 | $42,12944 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $40 | $30,53257 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $118 | $20,13533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Mount Pleasant
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.